Introduction
Repetitive transcranial magnetic stimulation (rTMS) is entering increasingly widespread use as an evidence-based treatment option for medication-resistant depression [1, 2] . Recent metaanalyses support the efficacy of rTMS in this population [3, 4] , with outcomes in recent reports approaching 45-55% response and 30-40% remission [5, 6, 7] . However, individual patients show considerable heterogeneity of outcomes, in a non-unimodal distribution, with distinct nonresponder and responder subpopulations [8, 9, 10] . Non-response is particularly burdensome for rTMS given that patients must commute to the clinic daily for 20-30 sessions [5, 11, 12] , with some recent studies suggesting longer courses may be required in some patients [13] . As such, early yet accurate prediction of non-response is desirable to facilitate early modification/augmentation of the treatment regimen.
Many studies have sought to identify predictive biomarkers of rTMS response. Candidate markers include clinical features, genetic polymorphisms, neurophysiological, and neuroimaging measures (for review, see [14] ). However, to date, no predictive biomarker has been adopted for routine clinical use. Two obstacles presently exist: accuracy and accessibility. Regarding accuracy, binary prediction of treatment outcome at the individual level presents a substantially higher bar than group-level correlation of a biomarker to outcome, which has been reported for diverse markers over the last 20 years. For example, group-level predictive correlations to outcome have been reported for serotonin transporter and brain-derived neurotrophic factor genetic polymorphisms [15, 16] , biochemical measures such as cortisol [17, 18] , baseline regional cerebral perfusion or metabolism on PET and SPECT [19] [20] [21] [22] [23] [24] , resting-state functional MRI [8, 25, 26] , quantitative EEG metrics [27] , and electrophysiological measures such as motor evoked potential amplitude, cortical silent period, or short-interval cortical inhibition [28] . A smaller number of studies have actually reported individual-level outcome prediction accuracies >80% for specific biomarkers, including quantitative EEG [29, 30] , and most recently, restingstate functional MRI [31] . Such developments are promising, but measures such as fMRI and TMS-electrophysiology are not readily available outside academic centers, limiting clinical utility. An individually accurate, yet widely accessible, approach to rTMS outcome prediction thus remains desirable.
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One straightforward approach that has proven helpful with other antidepressant treatment modalities is to track clinical response during early treatment. For example, with pharmacotherapy, large patient samples have revealed a bimodal distribution of outcomes into responders and non-responders [32, 33] . In a meta-analysis across 41 clinical trials enrolling 6562 patients, early improvement (≥20% symptom score reduction) in the first 2 weeks of treatment was an accurate predictor of stable response and remission [34] . Negative predictive value (NPV), at 82-100%, was substantially better that positive predictive value(PPV) (19-60%) in this study, suggesting that minimal improvement at 2 weeks might be used as a reliable predictor of non-response by treatment end. Indeed, early response, particularly at 2 weeks, has emerged as a reliable outcome predictor in a variety of other antidepressant studies (for detailed review, see [35] ). However, studies using conditional-probability measures such as NPV have also been criticized for applying arbitrary improvement thresholds (e.g., 30% [36] ); approaches surveying a range of thresholds (for example, signal detection theory [37] ) may thus be preferable.
How well does early clinical response compare to biological markers as an outcome predictor? A recent study [38] directly compared the predictive value of serological markers (serum and plasma BDNF increases at week 1) and EEG markers (prefrontal theta cordance) against simpler clinical markers (improvement on MADRS score at week 1 or 2). The best accuracy was obtained not with the biomarkers, but simply with a criterion of week 2 MADRS improvement ≤20%, achieving 92% NPV, versus 52-57% NPV for serological and 72% NPV for EEG markers. This report suggests that a simple metric of early clinical response may be able to match, or even exceed, the predictive performance of more complex, biologically based markers.
Although promising, the early-response approach to outcome prediction has seen only limited use for somatic therapies. For electroconvulsive therapy (ECT), a recent report in N=130 patients found that failure to achieve ≥20% improvement at 6 sessions was a strong predictor of nonremission (NPV, 100%) and a fair predictor of nonresponse (NPV, 75%); PPVs were substantially lower [39] . Taken together with the reports for antidepressant medications above, these results suggest that applying a minimum criterion of clinical improvement early in treatment (e.g., ≤20% improvement at 2 weeks) could be a reliable approach for identifying non-
responders, who could then be spared futile treatment and fast-tracked to an alternative treatment plan.
To our knowledge, no previous study has applied the early-response approach to outcome prediction for rTMS. However, given the logistical burdens of rTMS, early identification of nonresponders may be even more clinically relevant for rTMS than for medications. Thus, in this study, we aimed to determine whether early clinical response could be used accurately to identify rTMS non-responders.
Here, we present the results of a retrospective chart review in 101 patients who underwent a course of dorsomedial prefrontal cortex (DMPFC)-rTMS, to determine how accurately nonresponders could be identified at 2 weeks, based entirely on standardized clinical symptom scores. As in previous work in ECT [39] , we determined predictive accuracy for 2-week improvement across a range of clinically relevant cut-off criteria for early and late response. We focused specifically on NPV as the most clinically relevant performance metric, since the aim was to arrive at a decision rule for whether to change management (i.e., whether to modify treatment parameters, as opposed to proceeding with the full course as usual). Based on previous work, we hypothesized that a criterion of ≤20% improvement at 2 weeks (10 sessions) would achieve an NPV >80% in identifying patients who would prove to be rTMS non-responders at treatment end.
Materials and methods

Chart Review and Patient Population
Following parameters established in a previous case series on DMPFC-rTMS by our group [9] , this chart review included data from weekly self-rated symptom scales for adult (age ≥18) patients with a diagnosis of unipolar major depressive disorder and a current episode of major Following referral, all patients completed the Mini International Neuropsychiatric Interview (MINI) 6.0 screen, followed by a full clinical psychiatric assessment and multi-axial diagnosis by a Canadian Royal College-certified psychiatrist (JD or PG) using DSM-IV criteria, to establish the diagnosis of unipolar depression. All patients had a history of resistance to ≥2 adequate medication trials (including discontinuations due to adverse effects) in the current episode, based on clinical interview along with available medical/pharmacy records. As previously reported [9] , to maximize the generalizability of the reported results to real-world practice, no co-morbidities were used as exclusion criteria in this chart review, and regarding illness severity, treatment was offered to all patients with illness severe enough that they were sessions were also excluded; as previously reported [9] , in this cohort, no significant correlation was found between course length and degree of improvement.
All patients in this series maintained stable medications for 4 weeks prior to and throughout treatment. All patients provided informed consent for rTMS prior to initiating treatment. This chart review was approved by the University Health Network's Research Ethics Board.
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DMPFC-rTMS Technique
Motor threshold, navigation, and coil placement procedures for DMPFC-rTMS followed procedures that have been previously described in detail elsewhere [40, 41] . To summarize, rTMS was delivered using a MagPro R30 device via a Cool-DB80 Coil (MagVenture, Farum, Denmark) and a high-performance cooling system, under MRI guidance using the Visor 2.0 system (Advanced Neuro Technologies, Enschede, Netherlands) in all cases in this series.
Patients underwent left then right DMPFC at 120% resting motor threshold for extensor hallucis longus contractions. All patients in this series received 20 sessions of treatment, once daily on weekdays. Any missed sessions were added to the end of the treatment course, and no patient missed ≥4 cumulative sessions/course. Patients received either 10 Hz stimulation (3000 pulses per hemisphere), or intermittent theta-burst stimulation (iTBS) (600 pulses per hemisphere), as previously described [9] .
We have previously published results from this patient cohort demonstrating no differences in either the trajectories of outcome or the final treatment outcome between iTBS and 10 Hz protocols, whether on categorical or continuous measures, or on measures of the overall distribution of outcomes across the entire sample [9] . Moreover, we demonstrated no difference in trajectories of outcome even when the analysis was restricted to responders (i.e., those achieving ≥50% improvement). For these reasons, we included patients with iTBS and with 10
Hz stimulation in the present report. However, we also performed analyses to confirm that the distributions of outcomes did not differ between iTBS and 10 Hz patients (described below; Figure 1 ).
Clinical Assessments
Patients underwent baseline clinical assessments one week before treatment, weekly assessments (after every 5 sessions) during treatment, and a follow-up clinical assessment 2-6 weeks after
treatment. The primary outcome measure for the present analyses was the self-rated Beck Depression Inventory-II (BDI-II) [42] . The post-treatment score was defined as the first available follow-up clinical assessment in the window from 2 to 6 weeks post-treatment. The earlyresponse assessment points were defined at week 1 and week 2. The prediction metric at these timepoints was defined as the percentage improvement in BDI-II score, calculated using the pretreatment BDI-II score as the baseline.
As noted previously [9] , scores on the clinician-rated 17-item Hamilton Rating Scale for Depression (HamD17) were not consistently available at all timepoints for this patient sample, and were unavailable at all of the key time points (baseline, 1 week, 2 weeks, and post-treatment) in a substantial proportion of patients. For the purposes of the present analyses, the BDI-II also offers a more fine-grained scoring range compared to the HamD17, thus improving the precision of percentage-improvement assessments. Since we have previously reported similar categorical and continuous outcomes and a similar, trimodal outcome distribution for both self-report and clinical measures in this cohort [9] , in order to maximize the sample size and the precision of scoring, we focused on the BDI-II scale as the primary outcome measure for all analyses in this study.
Data Analysis
Data analyses were performed in the MATLAB environment (MathWorks, Natick, Massachusetts, USA), using standard built-in functions to generate cumulative distribution functions, estimate differences in distribution, perform kernel density estimates of the probability distribution function for outcomes, calculate negative predictive value across a range of earlyimprovement criteria and response criteria, and to compute the confusion matrices obtained using these criteria.
Results
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Demographics
A total of 101 patients (27% male, mean age 42.1±13.5) were included in the analysis. Out of 101, 64 patients received 10 Hz protocol and 37 received iTBS protocol as described above. The group receiving 10 Hz stimulation had a lower average age (10Hz 34.5±SD13.2, iTBS 46.5±SD11.6; Mann-Whitney U = 4.4, p < 0.01). There were no inter-group differences in male/female proportions (Chi-square test χ = 3.3, p =0.07), and no difference in any other clinical variables assessed, including pre-treatment depression severity, the duration of current episode, number of previous episodes, or number of previous medication trials (Table 1) .
Baseline illness severity, using conventional ranges, was mild (BDI 14-19) in 2/101, moderate {Insert Table 1 here}
Treatment Outcomes
Although we have previously reported no differences in response trajectory or distribution of iTBS and 10 Hz protocols in a cohort including this patient group [9] , we performed a verification analysis comparing the empirical cumulative distribution functions for the two treatment protocols in the present sample, both at the week 2 timepoint and at the post-treatment timepoint ( Figure 1 ). As distributions were non-normal, we employed the non-parametric two- For all analyses, to define responders and non-responders, we used the post-treatment BDI-II score and applied a conventional criterion of <50% improvement to distinguish responders from non-responders. In addition, we also repeated all analyses using a more strict criterion for nonresponse, on the grounds that some patients and clinicians might consider a 50% improvement to be worth completing the full course of treatment. Thus, we sought to identify a more stringently defined 'non-responder' group based on the data distribution itself.
Following previously employed methods [9, 10] , we performed a kernel density estimate to determine the overall distribution of responses (Figure 2 ). This distribution was trimodal, as previously noted [9] , and showed a distinct subgroup of individuals who achieved <35% improvement ( Figure 2) . We therefore repeated all subsequent analyses using a more stringent definition of 'non-responders' as those patients who achieved <35% improvement post-treatment.
{Insert Figure 2 here}
Negative Predictive Value Analyses
First, we assessed predictive value using the conventional nonresponse criterion of <50% improvement post-treatment. Using the Week 2 data, we computed NPV across a range of cutoff values from 0-50% improvement ( Figure 3A) . The plot showed a distinct step-function, with NPV values of 88-92% when cut-offs of <20% improvement were applied at week 2. When the criterion was relaxed beyond <20% improvement at Week 2, the resulting NPV declined markedly, plateauing at a much lower ~70% NPV for the remainder of the range. Narratively, for patients achieving less than 20% improvement at week 2, it was possible to be ~90% certain of nonresponse (<50% improvement at treatment end); however, for patients surpassing 20% improvement, it was much less possible to be certain of a poor outcome.
The full confusion matrix for <20% improvement at week 2 (in predicting <50% improvement at treatment end) showed a sensitivity of 85.7%, specificity of 76.4%, NPV of 88.2%, PPV of 72.0%, and overall accuracy of 80.0% ( Figure 3C ). Applying a more stringent cutoff of <10% improvement at week 2 did not notably improve performance; the confusion matrix at <10% M A N U S C R I P T
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showed a sensitivity of 90.5%, specificity of 56.6%, NPV of 89.5%, PPV of 60.3%, and overall accuracy of 71.3% ( Figure 3D ).
We next assessed predictive value for the more stringent, data-driven nonresponse criterion of <35% improvement post-treatment, again computing the NPV across the same range of Week 2 cut-off values from 0-50%( Figure 3B ). NPVs were slightly lower overall for this more stringent nonresponse definition, but still showed a distinctive step-function dropping off above the cutoff of <20% Week 2 improvement. NPV was in the range 81-88% with cutoffs of <20%, but dropped sharply to a plateau of <60% NPV beyond this point. The confusion matrix for <20% Weeks 2 improvement (in predicting <35% improvement at treatment end) showed a sensitivity of 80.0%, specificity of 80.4%, NPV of 80.4%, PPV of 80.0%, and overall accuracy of 80.2%
( Figure 3E ). Applying a more stringent cutoff of <10% improvement at week 2 only marginally improved performance; the confusion matrix at <10% showed a sensitivity of 90.0%, specificity of 64.7%, NPV of 86.8%, PPV of 71.4%, and overall accuracy of 77.2% ( Figure 3F ).
{Insert Figure 3 here}
Patients showing minimal response even during the first week of treatment (when non-specific social contact and behavioral activation effects may be prominent) could potentially be predicted to be poor responders. Thus, following previous work [38] , we conducted an additional analysis to see if NPV performance could be improved by using the best score achieved (i.e., the higher % improvement) at either week 1 or week 2 ( Figure 4A and 4B). NPVs were indeed slightly improved using this approach. For the <50% nonresponse criterion, NPVs were >90% for all cutoff criteria <20% improvement at week (1 or 2); beyond this cutoff, once again a stepfunction-like decline was observed, with deterioration of predictive performance towards an NPV of 70% ( Figure 4A ). There was less improvement on other measures achieved by using the best of Week (1 or 2) ; the full confusion matrix at <20% cutoff showed a sensitivity of 90.5%, specificity of 71.2%, NPV of 91.3%, PPV of 69.1%, and overall accuracy of 79.2% ( Figure 4C ), and at 10% cutoff showed a sensitivity of 95.2%, specificity of 49.2%, NPV of 93.5%, PPV of 57.1%, and overall accuracy of 68.3% ( Figure 4D ).
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Using the more stringent nonresponse criterion of <35% at treatment end, performance was also improved by including the best of Week (1 or 2), with NPVs in the range 85-95% below a <20% cutoff, deteriorating steadily with a less obvious step-function dropoff to 60% NPV at the end of the range ( Figure 4B ). Again, other measures were less improved; the full confusion matrix at <20% cutoff showed a sensitivity of 84%, specificity of 74.5%, NPV of 82.6%, PPV of 76.4%, and overall accuracy of 79.2% ( Figure 4E ), and at 10% cutoff showed a sensitivity of 96.0%, specificity of 56.9%, NPV of 93.5%, PPV of 68.6%, and overall accuracy of 76.2% ( Figure 4F ).
{Insert Figure 4 here}
Prediction Table for Nonresponse
Finally, as a potentially useful tool for the clinical setting, we generated a lookup table corresponding to the graphs in Figures 3 and 4 , to give the NPV for every cutoff % improvement level from 0-50%, with columns for both 50% nonresponder criterion and the 35% nonresponder criterion ( Table 2) . We generated such a table both for the Week 2 % improvement and for the best of Week (1 or 2) % improvement scores. Using these tables, for any given patient at Week 2 of treatment, it is possible to look up the chance of treatment nonresponse to DMPFC-rTMS, with nonresponse defined using either the 50% criterion or the more stringent 35% criterion. For example, given a patient whose best improvement across Week 1 or Week 2 was 18%, it is possible to advise that there is an 86% chance of achieving less than 35% improvement by treatment end, and a 95% chance of achieving less than 50% improvement by treatment end (example row indicated in italics).
Discussion
The prediction of treatment outcome based on early response, and in particular the degree of improvement at 2 weeks, is an approach that has proved fruitful for antidepressant medications in several studies over the last several years [34, 35, 38] . One lesson emerging from this literature M A N U S C R I P T
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is that NPV is consistently better than PPV -that is, prediction of nonresponse is substantially more reliable than prediction of treatment success [34] . However, since the default option at 2 weeks is usually to continue treatment, a test with high NPV is arguably more clinically useful, as it can be used to support a decision to change management (i.e., regimen or modality) and avoid futile treatment. Such a decision tool is all the more useful for a treatment that involves daily commutes to a clinic, and use of a limited resource (i.e., rTMS session capacity). As such, if 2-week improvement can be used as a high-NPV predictor of treatment outcome for rTMS, as for medications, the benefit for patients and providers could be substantial.
Our results indeed suggest that a lack of improvement at 2 weeks is an accurate predictor of rTMS nonresponse, with relatively high NPVs in the range of 80-90%. Using the best score of week 1 OR 2 yields a slight further improvement in NPV. These NPV ranges are similar to those previously reported for early treatment response for antidepressant pharmacotherapy and ECT in previous literature [34, 35, 38, 39] . These results suggest that the high NPV of early treatment response may be generalized from these modalities to rTMS. The use of a naturalistic rTMS clinic population, including both iTBS and 10 Hz stimulation protocols, also favors the generalizability of the results to clinical practice.
One notable observation in the present study was the sharp 'step-function' drop in NPV above a 20% cutoff for improvement at week 2, seen in all 4 analyses (Figures 3,4) . This observation suggests that for patients achieving ≤20% improvement by week 2, nonresponse can be predicted quite reliably at either the 50% or the more stringent 35% criterion. However, for patients who achieve better than 20% improvement by week 2, a poor outcome is less certain, and at least partial response becomes more likely. The pivotal value of 20% in the present study is in precise agreement with the same 20% cutoff identified in the recent predictor studies for pharmacotherapy [38] and ECT [39] described in the Introduction. The agreement raises the possibility that a '20% at 2 weeks' rule could be a modality-independent early criterion for treatment response in depression -a hypothesis worth future study.
A related point is that a '20% at 2 weeks'-type rule should be not be used automatically to exclude patients from further treatment with rTMS, any more than for medications; rather, as M A N U S C R I P T
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with medications, the rule may indicate when to modify the treatment regimen. For example, existing literature suggests that patients unresponsive to high-frequency rTMS may respond to low-frequency rTMS, or vice-versa [43] . Some patients unresponsive to unilateral rTMS may respond to bilateral rTMS, or patients unresponsive to DLPFC-rTMS may respond to DMPFCrTMS, as noted in recent treatment guidelines [2] . A lookup table of the type provided here (Table 2) can provide both parties with estimates of the likelihood of nonresponse, and this information can be used collaboratively to decide whether to persist, or switch rTMS protocols (e.g., to another site or stimulation pattern), or move to another modality entirely (e.g., ECT, magnetic seizure therapy, or novel pharmacotherapies such as ketamine).
Several important limitations of the present work will need to be addressed in future study. First, this study focused exclusively on DMPFC-rTMS rather than the more common DLPFC-rTMS.
Although the agreement of the findings with medication and ECT literature suggest generalizability, the analyses in the present study should nonetheless be repeated in a larger sample of patients undergoing DLPFC-rTMS. Second, this study used self-report questionnaires; although these are common mainstays of clinical practice, future studies should also employ clinician-rated scales. In addition, the effects of patient expectation were not captured in this dataset -an important area for future work. Finally, this study used treatment courses of 20 sessions, while many centers offer longer courses of 30 sessions, and a recent report identified a population of 'late responders' who emerge if additional twice-weekly rTMS is given after the acute course [13] . Presently, we lack sufficient information on whether the least responsive patients (e.g., 'stringent non-responders' at ≤35% improvement), seen in several studies [9, 10] , could convert to responders with extended courses beyond 20-30 sessions. Future studies should examine cohorts where every patient received longer courses of 30+ sessions; such studies could better characterize clinical/genotypic features of late-responders.
In conclusion, as the search continues for accurate biomarkers to predict rTMS treatment outcome, the alternative approach of using early clinical response at 2 weeks may be useful in Accordingly, the data from the patients undergoing these two treatment types was combined for subsequent analyses. The distribution of outcomes using kernel density estimate showed a non-normal (bimodal/trimodal) distribution with distinct non-responder and responder subgroups divided at a threshold of 35% improvement. This distribution suggests that a 35% cutoff for nonresponse may be a useful adjunct to the conventional cutoff of 50% in describing the outcomes in this dataset. 
